Ocugen

Basic Information

• Category: pharmaceutical industry
• Founded: 2015
• Website: http://ocugen.com/

Documented Facts

• Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
• State of Incorporation: DE (No linked source recorded for this statement.)
• Stock ticker: OCGN (Nasdaq) (No linked source recorded for this statement.)

Evidence and Sources

• Ocugen — Official Website (official)
• Ocugen, Inc. — SEC EDGAR (reference)

Citation Guidance

Explore pharmaceutical industry profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Ocugen.

• Canonical profile: https://brandsource.ai/brands/ocugen
• Machine-readable JSON-LD: https://brandsource.ai/api/brands/ocugen/json-ld
• Citation profile API: https://brandsource.ai/api/brands/ocugen/citation-profile
• Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
• Data status: Enriched
• Profile completeness: Source-backed profile (87/100)
• Indexing directive: index, follow, max-image-preview:large
• Recorded profile date: 2026-04-21

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases.

Available profile information

• Official website is captured for entity disambiguation.
• 1 official source linked for verification.
• 1 supporting source linked.
• 3 structured facts available for extraction.

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.